Metabolic Biomarkers in Hashimoto's Thyroiditis and Psoriasis
Metabolic Biomarkers in Hashimoto's Thyroiditis and Psoriasis
Hashimoto's disease (HT) and psoriasis (PsO) have a significant impact on patient's quality
 of everyday life, and early diagnosis is critical for the symptoms management and prognosis.
 There is evidence that HT and PsO share common metabolic pathways that relate to their
 pathogenesis, and are affected by dietary and lifestyle factors. Previous studies have
 identified potential metabolic biomarkers, although the small number of studies hamper their
 validation. Of note, most studies are not longitudinal thus do not capture the metabolic
 fluctuations in response to disease progression or dietary changes. Thus, the purpose of this
 study is to identify metabolic biomarkers of HT and PsO and study the role of epigenetic
 factors (diet and lifestyle) on the involved metabolic pathways . In addition, a comparative
 analysis of the disease-related quality of life (QoL) will be performed in relation to
 dietary changes to unravel possible links between the QoL and the associated metabolic
 pathways in HT and PsO.
Patients with Hashimoto's thyroiditis (HT), patients with psoriasis (PsO), and healthy
 individuals aged 18-60 will be recruited and assessed according to inclusion/exclusion
 criteria. Eligible participants will be randomized to two groups. The intervention group will
 receive a combinational nutraceuticals plan for 6 months as part of a Mediterranean diet and
 the control group will follow usual diet. Data will be collected at baseline and at the end
 of the study including levels of organic and fatty acids, lifestyle and anthropometric
 measurements, adherence to Mediterranean diet through the Mediterranean Diet Score (MDS) and
 disease-specific quality of life through the Thyroid Patient Report Outcome (THYPRO) and the
 Dermatology Life Quality Index (DLQI) questionnaires for the HT and the PsO group
 respectively.
Hashimoto's Thyroiditis:

 -  Clinical findings

 -  Presence of thyroid autoantibodies (anti-TPO) in laboratory tests

 -  Gray-scale Ultrasound findings.

 Psoriasis:

 -  Presence of psoriatic lesions

 -  Psoriasis Area and Severity Index score (PASI).

 Healthy group:

 Non-obese (BMI<30)

 -  non-athletes

 -  non-pregnant or lactating women

 -  not been diagnosed with a chronic or acute disease

 -  not receiving antidepressants, drugs and supplements

 -  normal Thyroid Stimulating Hormone (TSH) levels or high TSH and absence of other
 clinical findings of thyroid malfunction.

 Exclusion Criteria:

 -  malignant or congenital goiter

 -  thyroidectomy